|
Accrued expenses consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
March 31,
2023 |
|
|
December 31,
2022 |
|
|
|
|
|
|
|
|
Accrued pre-clinical and clinical costs |
|
$ |
4,074,713 |
|
|
$ |
2,137,317 |
|
Accrued product development costs |
|
|
409,691 |
|
|
|
247,500 |
|
Accrued compensation |
|
|
826,703 |
|
|
|
2,224,951 |
|
Accrued administrative costs |
|
|
143,175 |
|
|
|
473,376 |
|
Accrued interest |
|
|
1,014,020 |
|
|
|
916,108 |
|
Total |
|
$ |
6,468,302 |
|
|
$ |
5,999,252 |
|
|